Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next year
read at Endpoints ↗Positive readoutPositive
Inhibrx Biosciences announced that its OX40 agonist showed encouraging activity in a mid-stage trial involving immunogenic cancers.
The data suggest the agent may also enhance responses when paired with cancer vaccines, potentially expanding its use to tumors that are less immunogenic.
The company said it will begin studies combining the OX40 agonist with vaccine candidates early next year, aiming to evaluate safety and efficacy of the combination.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Inhibrx targets OX40 agonist-cancer vaccine studies from early next year”
read at Endpoints ↗89 words · retrieved Sep 8
comments(0)
5-min edit window · permanent after that